379 related articles for article (PubMed ID: 22003224)
1. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
Fujioka N; Nguyen J; Chen C; Li Y; Pasrija T; Niehans G; Johnson KN; Gupta V; Kratzke RA; Gupta K
Anesth Analg; 2011 Dec; 113(6):1353-64. PubMed ID: 22003224
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of EGF-induced ERK/MAP kinase-mediated astrocyte proliferation by mu opioids: integration of G protein and beta-arrestin 2-dependent pathways.
Miyatake M; Rubinstein TJ; McLennan GP; Belcheva MM; Coscia CJ
J Neurochem; 2009 Jul; 110(2):662-74. PubMed ID: 19457093
[TBL] [Abstract][Full Text] [Related]
3. The fibroblast growth factor receptor is at the site of convergence between mu-opioid receptor and growth factor signaling pathways in rat C6 glioma cells.
Belcheva MM; Haas PD; Tan Y; Heaton VM; Coscia CJ
J Pharmacol Exp Ther; 2002 Dec; 303(3):909-18. PubMed ID: 12438509
[TBL] [Abstract][Full Text] [Related]
4. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
[TBL] [Abstract][Full Text] [Related]
5. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells.
Thomas SM; Grandis JR; Wentzel AL; Gooding WE; Lui VW; Siegfried JM
Neoplasia; 2005 Apr; 7(4):426-31. PubMed ID: 15967120
[TBL] [Abstract][Full Text] [Related]
6. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.
Lennon FE; Mirzapoiazova T; Mambetsariev B; Poroyko VA; Salgia R; Moss J; Singleton PA
PLoS One; 2014; 9(3):e91577. PubMed ID: 24662916
[TBL] [Abstract][Full Text] [Related]
7. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
[TBL] [Abstract][Full Text] [Related]
9. RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
Xu ZH; Hang JB; Hu JA; Gao BL
Int J Clin Exp Pathol; 2013; 6(8):1493-504. PubMed ID: 23923067
[TBL] [Abstract][Full Text] [Related]
10. Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: implications for mitogen-activated protein kinase signaling.
Belcheva MM; Tan Y; Heaton VM; Clark AL; Coscia CJ
Mol Pharmacol; 2003 Dec; 64(6):1391-401. PubMed ID: 14645669
[TBL] [Abstract][Full Text] [Related]
11. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
[TBL] [Abstract][Full Text] [Related]
12. mu-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation.
Belcheva MM; Szùcs M; Wang D; Sadee W; Coscia CJ
J Biol Chem; 2001 Sep; 276(36):33847-53. PubMed ID: 11457825
[TBL] [Abstract][Full Text] [Related]
13. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
14. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.
VanMeter AJ; Rodriguez AS; Bowman ED; Jen J; Harris CC; Deng J; Calvert VS; Silvestri A; Fredolini C; Chandhoke V; Petricoin EF; Liotta LA; Espina V
Mol Cell Proteomics; 2008 Oct; 7(10):1902-24. PubMed ID: 18687633
[TBL] [Abstract][Full Text] [Related]
15. Morphine Prevents Ischemia/Reperfusion-Induced Myocardial Mitochondrial Damage by Activating δ-opioid Receptor/EGFR/ROS Pathway.
Xu J; Bian X; Zhao H; Sun Y; Tian Y; Li X; Tian W
Cardiovasc Drugs Ther; 2022 Oct; 36(5):841-857. PubMed ID: 34279751
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
17. Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
Lypova N; Telang S; Chesney J; Imbert-Fernandez Y
J Biol Chem; 2019 Jul; 294(27):10530-10543. PubMed ID: 31126985
[TBL] [Abstract][Full Text] [Related]
18. Arsenic activates EGFR pathway signaling in the lung.
Andrew AS; Mason RA; Memoli V; Duell EJ
Toxicol Sci; 2009 Jun; 109(2):350-7. PubMed ID: 19168569
[TBL] [Abstract][Full Text] [Related]
19. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA
Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
